Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Gregory Richard Schwartz, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Bitton A, Schwartz GR, Stewart EE, Henderson DE, Keohane CA, Bates DW, Schiff GD. Off the hamster wheel? Qualitative evaluation of a payment-linked patient-centered medical home (PCMH) pilot. Milbank Q. 2012 Sep; 90(3):484-515. PMID: 22985279.
    Citations: 14     Fields:    Translation:Humans
  2. Ryu SK, Mallat Z, Benessiano J, Tedgui A, Olsson AG, Bao W, Schwartz GG, Tsimikas S. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation. 2012 Feb 14; 125(6):757-66. PMID: 22230483.
    Citations: 27     Fields:    Translation:HumansCells
  3. Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, Ostadal P, Macin SM, Liem AH, Mills E, Bhatnagar N, Bucher HC, Briel M. Statins for acute coronary syndrome. Cochrane Database Syst Rev. 2011 Jun 15; (6):CD006870. PMID: 21678362.
    Citations: 12     Fields:    Translation:Humans
  4. Schwartz GG, Chaitman BR, Goldberger JJ, Messig M. High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Am Heart J. 2011 May; 161(5):993-9. PMID: 21570534.
    Citations: 12     Fields:    Translation:Humans
  5. Briel M, Vale N, Schwartz GG, de Lemos JA, Colivicchi F, den Hartog FR, Ostadal P, Macin SM, Liem A, Mills E, Bhatnagar N, Bucher HC, Nordmann AJ. Updated evidence on early statin therapy for acute coronary syndromes: meta-analysis of 18 randomized trials involving over 14,000 patients. Int J Cardiol. 2012 Jun 28; 158(1):93-100. PMID: 21295870.
    Citations: 8     Fields:    Translation:Humans
  6. Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J. 2009 Dec; 158(6):896-901.e3. PMID: 19958854.
    Citations: 60     Fields:    Translation:Humans
  7. Schwartz GG. High-density lipoprotein cholesterol as a risk factor and target of therapy after acute coronary syndrome. Am J Cardiol. 2009 Nov 16; 104(10 Suppl):46E-51E. PMID: 19895944.
    Citations: 3     Fields:    Translation:HumansAnimalsPHPublic Health
  8. Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009 Jun 09; 53(23):2186-96. PMID: 19497447.
    Citations: 37     Fields:    Translation:HumansCells
  9. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Bao W, Libby P, Ganz P. Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study. Atherosclerosis. 2009 Oct; 206(2):551-5. PMID: 19394618.
    Citations: 4     Fields:    Translation:Humans
  10. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Szarek M, Waters DD, Libby P, Ganz P. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study. Arterioscler Thromb Vasc Biol. 2008 Jan; 28(1):142-7. PMID: 17991875.
    Citations: 26     Fields:    Translation:Humans
  11. Evans-Molina C, Regan S, Henault LE, Hylek EM, Schwartz GR. The new Medicare Part D prescription drug benefit: an estimation of its effect on prescription drug costs in a Medicare population with atrial fibrillation. J Am Geriatr Soc. 2007 Jul; 55(7):1038-43. PMID: 17608876.
    Citations: 7     Fields:    Translation:Humans
  12. Olsson AG, Schwartz GG, Szarek M, Luo D, Jamieson MJ. Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). Am J Cardiol. 2007 Mar 01; 99(5):632-5. PMID: 17317362.
    Citations: 12     Fields:    Translation:Humans
  13. Briel M, Schwartz GG, Thompson PL, de Lemos JA, Blazing MA, van Es GA, Kayikçioglu M, Arntz HR, den Hartog FR, Veeger NJ, Colivicchi F, Dupuis J, Okazaki S, Wright RS, Bucher HC, Nordmann AJ. Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. JAMA. 2006 May 03; 295(17):2046-56. PMID: 16670413.
    Citations: 26     Fields:    Translation:Humans
  14. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care. 2005 Oct; 28(10):2508-13. PMID: 16186288.
    Citations: 14     Fields:    Translation:Humans
  15. Schwartz GG, Olsson AG. The case for intensive statin therapy after acute coronary syndromes. Am J Cardiol. 2005 Sep 05; 96(5A):45F-53F. PMID: 16126023.
    Citations: 7     Fields:    Translation:Humans
  16. Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J. 2005 May; 26(9):890-6. PMID: 15764620.
    Citations: 43     Fields:    Translation:HumansCTClinical Trials
  17. Schwartz GG. Statins in acute coronary syndromes: the sooner, the better? Am Heart J. 2005 Mar; 149(3):377-80. PMID: 15864223.
    Citations:    Fields:    Translation:HumansPHPublic Health
  18. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004 Sep 14; 110(11):1406-12. PMID: 15353498.
    Citations: 45     Fields:    Translation:HumansCellsCTClinical Trials
  19. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, Ganz P, Libby P. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004 Jul 27; 110(4):386-91. PMID: 15262833.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  20. Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, Cressman M. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Am Heart J. 2004 Jul; 148(1):e4. PMID: 15215813.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  21. Schwartz GG, Ganz P, Waters D, Arikian S. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. Am J Cardiol. 2003 Nov 01; 92(9):1109-12. PMID: 14583367.
    Citations: 6     Fields:    Translation:HumansPHPublic Health
  22. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Leslie SJ, Sasiela WJ, Szarek M, Libby P, Ganz P. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003 Sep 30; 108(13):1560-6. PMID: 12975259.
    Citations: 77     Fields:    Translation:HumansCTClinical Trials
  23. Xu Y, Lu L, Greyson C, Lee J, Gen M, Kinugawa K, Long CS, Schwartz GG. Deleterious effects of acute treatment with a peroxisome proliferator-activated receptor-gamma activator in myocardial ischemia and reperfusion in pigs. Diabetes. 2003 May; 52(5):1187-94. PMID: 12716751; PMCID: PMC3633427.
    Citations: 8     Fields:    Translation:Animals
  24. Olsson AG, Schwartz GG, Jonasson L, Linderfalk C. Are early clinical effects of cholesterol lowering mediated through effects on inflammation? Acta Physiol Scand. 2002 Oct; 176(2):147-50. PMID: 12354174.
    Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
  25. Waters DD, Schwartz GG, Olsson AG, Zeiher A, Oliver MF, Ganz P, Ezekowitz M, Chaitman BR, Leslie SJ, Stern T. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002 Sep 24; 106(13):1690-5. PMID: 12270864.
    Citations: 32     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  26. Schwartz GG, Olsson AG. Lipid lowering in acute coronary syndromes: new evidence, new questions. Curr Atheroscler Rep. 2002 Jan; 4(1):1-3. PMID: 11772415.
    Citations:    Fields:    Translation:HumansPHPublic Health
  27. Olsson AG, Schwartz GG. Early initiation of treatment with statins in acute coronary syndromes. Ann Med. 2002; 34(1):37-41. PMID: 12014432.
    Citations: 4     Fields:    Translation:Humans
  28. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR. Atorvastatin for acute coronary syndromes. JAMA. 2001 Aug 01; 286(5):533-5. PMID: 11476650.
    Citations: 1     Fields:    Translation:Humans
  29. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001 Apr 04; 285(13):1711-8. PMID: 11277825.
    Citations: 433     Fields:    Translation:HumansCTClinical Trials
  30. Schwartz GG, Oliver MF, Ezekowitz MD, Ganz P, Waters D, Kane JP, Texter M, Pressler ML, Black D, Chaitman BR, Olsson AG. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. Am J Cardiol. 1998 Mar 01; 81(5):578-81. PMID: 9514453.
    Citations: 9     Fields:    Translation:Humans
  31. Schwartz GR. Medical students' burdens include debt. JAMA. 1996; 275(17):1370.
  32. Schwartz GR. Students speak on health system reform. JAMA. 1995 Jan 04; 273(1):76. PMID: 7996655.
    Citations:    Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Schwartz's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (149)
Co-Authors (8)
Similar People (60)
Same Department 
Physical Neighbors
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.